These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

116 related items for PubMed ID: 8431975

  • 1. 1-dehydro-melengestrol acetate inhibits the growth and protein kinase C activity of androgen-independent Dunning rat prostatic tumors.
    Battistone MJ, Padilla GM, Petrow V.
    Cancer Chemother Pharmacol; 1993; 31(5):407-11. PubMed ID: 8431975
    [Abstract] [Full Text] [Related]

  • 2. Melengestrol acetate and megestrol acetate are prostatic tumor inhibiting agents.
    Padilla GM, Yacullo RC, Padilla JJ, Payne B, Petrow V.
    Biochem Cell Biol; 1990 Oct; 68(10):1181-8. PubMed ID: 2268413
    [Abstract] [Full Text] [Related]

  • 3. Antitumoral effects of liarozole in androgen-dependent and independent R3327-Dunning prostate adenocarcinomas.
    Dijkman GA, Van Moorselaar RJ, Van Ginckel R, Van Stratum P, Wouters L, Debruyne FM, Schalken JA, de Coster R.
    J Urol; 1994 Jan; 151(1):217-22. PubMed ID: 8254818
    [Abstract] [Full Text] [Related]

  • 4. Sustained in vivo regression of Dunning H rat prostate cancers treated with combinations of androgen ablation and Trk tyrosine kinase inhibitors, CEP-751 (KT-6587) or CEP-701 (KT-5555).
    George DJ, Dionne CA, Jani J, Angeles T, Murakata C, Lamb J, Isaacs JT.
    Cancer Res; 1999 May 15; 59(10):2395-401. PubMed ID: 10344749
    [Abstract] [Full Text] [Related]

  • 5. An inhibitory effect of TZP-4238 on the growth of androgen-sensitive rat prostatic tumor (Dunning R3327).
    Ichikawa T, Akimoto S, Shimazaki J.
    Endocr J; 1993 Aug 15; 40(4):425-30. PubMed ID: 7522799
    [Abstract] [Full Text] [Related]

  • 6. Effect of active immunization against luteinizing hormone-releasing hormone on the androgen-sensitive Dunning R3327-PAP and androgen-independent Dunning R3327-AT2.1 prostate cancer sublines.
    Fuerst J, Fiebiger E, Jungwirth A, Mack D, Talwar PG, Frick J, Rovan E.
    Prostate; 1997 Jul 01; 32(2):77-84. PubMed ID: 9215394
    [Abstract] [Full Text] [Related]

  • 7. Differential androgenic control of prostatic cytosolic cAMP-dependent and -independent protein kinases.
    Tse EY, Goueli SA, Ahmed K.
    Arch Biochem Biophys; 1984 Apr 01; 230(1):39-48. PubMed ID: 6712245
    [Abstract] [Full Text] [Related]

  • 8. Antiproliferative and antimetastatic effects of gossypol on Dunning prostate cell-bearing Copenhagen rats.
    Chang CJ, Ghosh PK, Hu YF, Brueggemeier RW, Lin YC.
    Res Commun Chem Pathol Pharmacol; 1993 Mar 01; 79(3):293-312. PubMed ID: 8480076
    [Abstract] [Full Text] [Related]

  • 9. Inhibitory effects of somatostatin analogue RC-160 and bombesin/gastrin-releasing peptide antagonist RC-3095 on the growth of the androgen-independent Dunning R-3327-AT-1 rat prostate cancer.
    Pinski J, Reile H, Halmos G, Groot K, Schally AV.
    Cancer Res; 1994 Jan 01; 54(1):169-74. PubMed ID: 7903203
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Regulation of expression of Na+,K+-ATPase in androgen-dependent and androgen-independent prostate cancer.
    Blok LJ, Chang GT, Steenbeek-Slotboom M, van Weerden WM, Swarts HG, De Pont JJ, van Steenbrugge GJ, Brinkmann AO.
    Br J Cancer; 1999 Sep 01; 81(1):28-36. PubMed ID: 10487609
    [Abstract] [Full Text] [Related]

  • 12. Effect of cyproterone acetate in comparison to flutamide on the ventral prostate of adult male castrated Copenhagen-Fisher rats and on Dunning R-3327 H tumors.
    Donn F, Becker H, Klosterhalfen H, Klein H.
    Andrologia; 1989 Sep 01; 21(5):462-7. PubMed ID: 2530921
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Unusual androgen sensitivity of the androgen-independent Dunning R-3327-G rat prostatic adenocarcinoma: androgen effect on tumor cell loss.
    Humphries JE, Isaacs JT.
    Cancer Res; 1982 Aug 01; 42(8):3148-56. PubMed ID: 7093958
    [Abstract] [Full Text] [Related]

  • 15. The protein kinase C activator, phorbol ester, elicits disparate functional responses in androgen-sensitive and androgen-independent human prostatic cancer cells.
    Henttu P, Vihko P.
    Biochem Biophys Res Commun; 1998 Mar 06; 244(1):167-71. PubMed ID: 9514905
    [Abstract] [Full Text] [Related]

  • 16. Increased fatty acid synthase as a therapeutic target in androgen-independent prostate cancer progression.
    Pizer ES, Pflug BR, Bova GS, Han WF, Udan MS, Nelson JB.
    Prostate; 2001 May 01; 47(2):102-10. PubMed ID: 11340632
    [Abstract] [Full Text] [Related]

  • 17. Acid phosphatase-producing androgen-independent subline of rat prostatic adenocarcinoma (Dunning R3327 tumor) in cell culture.
    Igarashi T, Isaka S, Miyauchi T, Hayata I, Shimazaki J.
    Prostate; 1984 May 01; 5(1):113-22. PubMed ID: 6694915
    [Abstract] [Full Text] [Related]

  • 18. Differential expression of protein kinase C isozyme messenger RNAs in dunning R-3327 rat prostatic tumors.
    Powell CT, Fair WR, Heston WD.
    Cell Growth Differ; 1994 Feb 01; 5(2):143-9. PubMed ID: 8180127
    [Abstract] [Full Text] [Related]

  • 19. Protein kinase C-alpha: a novel target for the therapy of androgen-independent prostate cancer? (Review-hypothesis).
    O'Brian CA.
    Oncol Rep; 1998 Feb 01; 5(2):305-9. PubMed ID: 9468546
    [Abstract] [Full Text] [Related]

  • 20. Inositol hexaphosphate inhibits growth and induces G1 arrest and apoptotic death of androgen-dependent human prostate carcinoma LNCaP cells.
    Agarwal C, Dhanalakshmi S, Singh RP, Agarwal R.
    Neoplasia; 2004 Feb 01; 6(5):646-59. PubMed ID: 15548374
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.